Target Name: SVOPL
NCBI ID: G136306
Other Name(s): putative transporter SVOPL | SVOPL variant 1 | Putative transporter SVOPL | solute carrier family 22 member B5 | Putative transporter SVOPL (isoform 1) | SVOP-like protein | SV2-related protein-like | SVOP like, transcript variant 1 | SVOP like | SVOPL_HUMAN | SLC22B5 | SV2 related protein homolog-like

SVOPL: A Potential Drug Target for Neural Disorders

Synaptic vesicle-oriented protein (SVOPL) is a protein that is expressed in the nervous system and has been shown to play a role in the transmission of information between neurons. It is also known as the putative transporter SVOPL and has been identified as a potential drug target for various neurological and psychiatric disorders.

SVOPL is a protein that is composed of 21 kDa monomeric subunits and has a calculated molecular mass of 24.3 kDa. It is located in the cell body and is predominantly expressed in the postsynaptic terminal of neurons. SVOPL is involved in the transport of different types of molecules, including neurotransmitters, across the synapse.

SVOPL is a putative transporter, which means that it is involved in the transport of molecules across a membrane. It is known to have a high affinity for neurotransmitters, such as dopamine, serotonin, and GABA, which are involved in various neural functions. This suggests that SVOPL may be a drug target for disorders that are characterized by abnormal neurotransmitter levels or dysfunction in the nervous system.

SVOPL has been shown to play a role in the regulation of synaptic transmission in the nervous system. It has been shown to interact with various intracellular signaling pathways, including the cAMP/protein kinase A (PKA) signaling pathway. This suggests that SVOPL may be involved in the regulation of intracellular signaling pathways that are important for neural function.

SVOPL has also been shown to be involved in the regulation of synaptic plasticity, which is the ability of the nervous system to change and adapt over time. This suggests that SVOPL may be involved in the regulation of neural plasticity, which is important for the development and maintenance of neural circuits.

In addition to its role in synaptic transmission and plasticity, SVOPL has also been shown to be involved in the regulation of neurotrophic factor (NTF) signaling, which is a signaling pathway that is important for the survival and growth of neurons. This suggests that SVOPL may be involved in the regulation of NTF signaling, which is important for the maintenance of neural function.

SVOPL has also been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and apoptosis. This suggests that SVOPL may be involved in the regulation of cellular processes that are important for the development and maintenance of neural circuits.

Given its involvement in various cellular processes that are important for neural function, SVOPL may be a potential drug target for disorders that are characterized by abnormal neural function. For example, SVOPL has been shown to be involved in the regulation of neurotransmitter release in the nervous system, which may be important for the treatment of disorders such as depression, anxiety, and schizophrenia. Additionally, SVOPL may be involved in the regulation of synaptic plasticity, which is important for the development and maintenance of neural circuits. This may make SVOPL a potential drug target for disorders such as Alzheimer's disease and other forms of neurodegenerative disorder.

In conclusion, SVOPL is a protein that is involved in various cellular processes that are important for neural function. It has been shown to play a role in the regulation of neurotransmission, synaptic plasticity, and cellular processes that are important for the development and maintenance of neural circuits. As a result, SVOPL may be a potential drug target for disorders characterized by abnormal neural function. Further research is needed to fully understand the role of SVOPL in neural function and to determine its potential as a drug target.

Protein Name: SVOP Like

More Common Targets

SWAP complex | SWAP70 | SWI5 | SWI5-SFR1 complex | SWINGN | SWSAP1 | SWT1 | SYAP1 | SYBU | SYCE1 | SYCE1L | SYCE2 | SYCE3 | SYCN | SYCP1 | SYCP2 | SYCP2L | SYCP3 | SYDE1 | SYDE2 | SYF2 | SYK | SYMPK | SYN1 | SYN2 | SYN3 | Synaptotagmin | SYNC | SYNCRIP | Syndecan | SYNDIG1 | SYNDIG1L | SYNE1 | SYNE1-AS1 | SYNE2 | SYNE3 | SYNE4 | SYNGAP1 | SYNGR1 | SYNGR2 | SYNGR3 | SYNGR4 | SYNJ1 | SYNJ2 | SYNJ2BP | SYNM | SYNM-AS1 | SYNPO | SYNPO2 | SYNPO2L | SYNPO2L-AS1 | SYNPR | SYNPR-AS1 | SYNRG | Syntaxin | Synuclein | SYP | SYPL1 | SYPL2 | SYS1 | SYS1-DBNDD2 | SYT1 | SYT10 | SYT11 | SYT12 | SYT13 | SYT14 | SYT15 | SYT15B | SYT16 | SYT17 | SYT2 | SYT3 | SYT4 | SYT5 | SYT6 | SYT7 | SYT8 | SYT9 | SYTL1 | SYTL2 | SYTL3 | SYTL4 | SYTL5 | SYVN1 | SZRD1 | SZRD1P1 | SZT2 | T-Box transcription factor (TBX) | T-Type Calcium Channel | TAAR1 | TAAR2 | TAAR3P | TAAR5 | TAAR6 | TAAR8 | TAAR9 | TAB1 | TAB2 | TAB2-AS1